Verdant Minerals Ltd
Verdant Minerals Ltd (ASX: VRM) is headquartered in Australia. The company is engaged in the exploration and evaluation of fertilizers and other minerals (potash, silica, phosphate and high purity quartz rock) in northern and central Australia. As of date, the company has a market capitalization of AUD 34.22 million. At the end of the trading session, on 12 March 2019, the VRM’s stock price closed at AUD 0.030, down by 3.226% from its previous close. However, the stock has yielded impressive return of 106.67% this year as on 11 March.
On 11 March 2019, the company’s announced that it has signed a scheme implementation agreement, governing the acquisition of all the issued shares in VRM by CD Capital Natural Resources Fund III LP. These exclude shares/interest held by Washington H. Soul Pattinson and Company Limited (WHSP). Upon implementation of the Scheme, VRM shareholders will receive a significant premium of $ 0.032 per VRM share held until the Scheme record date. As of the quarter ended December 31st, 2018, the company had net cash and cash equivalents of AUD 893K.
EMU NL (ASX: EMU) is a Perth-based company which explores mineral properties (gold, silver, copper, lead, and zinc deposits) in Chile. It holds an option to acquire 100% stake in the Vidalita and Jotahues gold projects encompassing 13,750 hectares of mineral exploration tenements in Atacama region’s Maricunga gold belt in northern Chile. With the end of the trading session on March 12th, 2019, the EMU stock price stood at AUD 0.080, down by 5.882% from its previous close. However, the stock has yielded outstanding YTD return of 88.89% as on 11 March.
Recently, the company reported assay results from the fast-moving air core (AC) drilling campaign at the Vidalita Prospect in Maricunga Belt, Chile. Around two broad zones of vuggy silica and breccia were intersected from the hole 5300-8, representing highest grade gold-silver deposit similar to Salares Norte. For the quarter ended December 31st, 2018, the company’s net cash and cash equivalents came to the value of around AUD 1.16 million. There were net cash outflows of AUD 552K from operating activities and major cash inflows of AUD 1.41 million from financing activities. Besides, cash outflows of around AUD 810K are estimated for the next quarter.
Admedus Ltd (ASX: AHZ) is a medical technology company that offers, clinical solutions to assist healthcare professionals. Its proprietary product is the ADAPT technology which produces implantable tissue bio-scaffolds for a number of cardiovascular and vascular applications. With the end of the trading session on 12 March 2019, the stock of the company stood at A$0.40, down by 16.667 % from its previous close. Although the stock has soared by 60% over last five days.
Recently, on March 11th, 2019, the company’s CardioCel 3D product portfolio and the collagen bioscaffold VascuCel, both received regulatory sanctions for sale in Europe. The first phase of commercial launch is scheduled for the end of 2019. As per the company’s Preliminary Final report for the year ended December 31st, 2018, the revenue was recorded at $ 25.6 million for the financial year, up 20% on $ 21.4 million in FY2017. The gross profit for the group for the year was $12.4 million representing a gross profit margin of 49% and the net loss after tax was $24.7 million. As on December 2018, the closing cash balance was $12.0 million, up from $8.3 million as at December 31st, 2017.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.